Source: Pharamceutical Technology

IDRx received $120M in Series B Funding

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Tim Clackson

CEO Approval Rating

90/100

IDRx is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops precision therapies for the treatment of cancer.